ECTE Financial Facts

Net loss per common share, basic and diluted: -0.97
Licensing revenue: 0
See Full Income Statement

Prepaid expenses and other current assets: 342.97K
Additional paid-in capital: 145.26M
See Full Balance Sheet

Echo Therapeutics (ECTE) Earnings

  |   Expand Research on ECTE
Next EPS Date 11/19/15 *Est. EPS Growth Rate -212.9% *Last Qtr.
Average EPS % Beat Rate +9.5% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS -14.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/14/15 Q215 -$0.97N/A N/A N/AN/A N/A Details
11/19/14 Q314 -$0.43N/A N/A $19.11M$22.56M N/A Details
8/14/14 Q214 -$0.31-$0.23 -$0.08$19.1M$22.56M N/A Details
5/9/14 Q114 -$0.23-$0.31 +$0.08$19.11K$20K N/A Details
3/27/14 Q413 -$0.36-$0.40 +$0.04N/A$20K N/A Details
8/8/13 Q213 -$0.51-$0.81 +$0.30$22.56M$10M N/A Details
5/10/13 Q113 -$0.13-$0.10 -$0.03N/A$10K N/A Details
11/8/12 Q312 -$0.11-$0.09 -$0.02$30.9K$40K N/A Details